ETC
LGND icon

Exchange Traded Concepts’s Ligand Pharmaceuticals LGND Stock Holding History

Exchange Traded Concepts’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,140
Closed -$357K – 1500
2025
Q2 		$357K Buy
3,140
+1,987
+172% +$212K ﹤0.01% 967
2025
Q1 		$121K Buy
1,153
+1,070
+1,289% +$121K ﹤0.01% 1087
2024
Q4 		$8.89K Buy
+83
New +$9.38K ﹤0.01% 1302

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Exchange Traded Concepts's LGND Position: Q3 2025 in Review

Exchange Traded Concepts sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 3,140 shares — an estimated $357K sold.

Exchange Traded Concepts first reported a position in LGND in Q4 2024 and held it in 3 quarters. The position peaked at $357K in Q2 2025. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • Exchange Traded Concepts reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 3,140 Ligand Pharmaceuticals shares in Q3 2025, an estimated $357K.
  • Exchange Traded Concepts first reported a position in Ligand Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Exchange Traded Concepts's Ligand Pharmaceuticals position peaked at $357K in Q2 2025.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Exchange Traded Concepts's 13F filing for Q3 2025, filed 14 Oct 2025.